Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This study offers longitudinal insight into the impact of three SARS-CoV-2 vaccinations on humoral and cellular immunity in patients with solid cancers, patients with hematologic malignancies, and persons without cancer. For all cohorts, virus-neutralizing immunity was significantly depleted over a period of up to 9 months following the second vaccine dose, the one striking exception being IL2 production by SARS-CoV-2 antigen-specific T cells. Immunity was restored by the third vaccine dose, except in a substantial number of patients with hematologic malignancy, for whom both cancer type and treatment schedule were associated with nonresponse. Thus, whereas most patients with myelodysplastic syndrome were conspicuously good responders, some patients with other hematologic malignancies receiving cancer therapies within 2 weeks of vaccination showed no seroconversion despite three vaccine doses. Moreover, SARS-CoV-2 exposure during the course of the study neither prevented immunity waning, even in healthy controls, nor guaranteed vaccine responsiveness. These data offer real-world human immunologic insights that can inform health policy for patients with cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614214 | PMC |
| http://dx.doi.org/10.1158/2767-9764.CRC-22-0298 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Evaluation of Mission and Vision Statements from NCI-designated Cancer Centers and Their Affiliated Hospitals.
Oncologist
September 2025
Section of Hematology/Oncology, Department of Medicine, Stephenson Cancer Center and the University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Background: Effective communication of mission and vision statements (MVS) is important for medical institutions seeking to connect with patients, staff, and the community. This study assessed the composition, readability, and topics addressed within MVS among NCI-designated cancer centers and affiliated hospitals.
Methods: We extracted MVS data from institutional websites for 65 NCI-designated cancer centers and their affiliated hospitals.
Accurate tacrolimus monitoring by dual peripherally inserted central catheters in allogeneic HSCT.
Int J Hematol
September 2025
Department of Hematology and Oncology, Asahikawa Red Cross Hospital, 1-1 Akebono-Cho, Asahikawa, Hokkaido, Japan.
Introduction: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) requires reliable vascular access for medication, transfusion, and blood sampling, which often involves painful venipuncture. This prospective study evaluated a novel dual peripherally inserted central venous catheter (PICC) technique to reduce venipuncture frequency in allo-HSCT recipients.
Methods: The study enrolled 29 allo-HSCT recipients.
Published Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients.
Target Oncol
September 2025
Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Background: Population pharmacokinetic models can potentially provide suggestions for an initial dose and the magnitude of dose adjustment during therapeutic drug monitoring procedures of imatinib. Several population pharmacokinetic models for imatinib have been developed over the last two decades. However, their predictive performance is still unknown when extrapolated to different populations, especially children.
View Article and Find Full Text PDFThe Discovery of RP-2119: A Potent, Selective, and Orally Bioavailable Polθ ATPase Inhibitor.
J Med Chem
September 2025
Repare Therapeutics, 7171 Frederick-Banting, Building 2, H4S 1Z9 Montréal, Québec, Canada.
DNA polymerase theta (Polθ) plays a critical role in repairing DNA double-strand breaks through microhomology-mediated end joining (MMEJ) and has emerged as a key synthetic lethal drug target in cancers with homologous recombination (HR) deficiencies. Its inhibition has shown a strong potential to synergize with PARP inhibitors, particularly in tumors with deleterious or mutations. Here, we describe the discovery and preclinical development of RP-2119, a selective, potent, and bioavailable Polθ ATPase inhibitor.
View Article and Find Full Text PDFThe International Association for the Study of Lung Cancer Staging Project: The Impact of Smoking Status on Lung Cancer Staging in the Ninth Edition of the TNM Classification.
J Thorac Oncol
August 2025
Department of Radiation Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky.
Introduction: Cigarette smoking negatively affects lung cancer prognosis. Incorporating smoking history into stage-stratified survival analyses may improve prognostication.
Methods: Using the International Association for the Study of Lung Cancer ninth edition NSCLC database, we evaluated the association between smoking status at diagnosis and overall survival (OS) using Kaplan-Meier plots and multivariate Cox proportional hazard regression models adjusted for age, region, sex, histologic type, performance status, and TNM stage.